1 October 2014
EFPIA Japan

Carsten Brunn to become new chairman of EFPIA JapanTOKYO—1 October 2014— EFPIA Japan announced today that Carsten Brunn(President and Representative Director, Bayer Yakuhin, Ltd.) has been appointed the newchairman of EFPIA Japan effective 10 October 2014.
Philippe Fauchet (GlaxoSmithKline K.K.) and Masao Torii (Nippon Boehringer IngelheimCo., Ltd.) will continue to serve in their current positions of vice chairmen and support
Carsten Brunn in his new role.
“As Japanese society changes, the Japanese healthcare environment also continues toevolve. As EFPIA Japan, we are committed to fostering healthcare for patients in Japan,”said Carsten Brunn. “We support Japan’s commitments to reform healthcare and further
improve patient access to high-quality healthcare and creating an environment that
supports innovation. In my new role I will continue to promote the collaborative exchangeof ideas between the research-based industry and its many stakeholders in Japan.”

EFPIA Japan Board Members as of 10 October 2014
Chairman
Carsten Brunn (Bayer Yakuhin, Ltd.)
Vice Chairmen
Philippe Fauchet (GlaxoSmithKline K.K.)
Masao Torii (Nippon Boehringer Ingelheim Co., Ltd.)
Directors
Gabriel Baertchi (AstraZeneca K.K.)
Dirk Kosche (Novartis Pharma K.K.) *Suspension
Claus Eilersen (Novo Nordisk Pharma Ltd.)James Feliciano (Merck Serono Co., Ltd.)
Fabrice Baschiera (Sanofi K.K.)
Director General
Hidetaka Shimada (EFPIA Japan)

New

New

__________________________________________________________________
c/o Sanofi K.K.
Tokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo 163-1488
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

About EFPIA Japan:
Established in April 2002, EFPIA Japan represents 24 R&D-based European
pharmaceutical companies operating in Japan. In 2013, combined sales from the member
companies accounted for roughly 26% of the pharmaceutical market in Japan.
Mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan by early
introduction of innovative medicines and vaccines”, and by always focusing on the 'patient
first', it hopes to strengthen dialogues with decision makers to improve Japanese
healthcare.
About EFPIA:EFPIA represents the pharmaceutical industry operating in Europe. Through its
direct membership of 33 national associations and 40 leading pharmaceutical companies,
EFPIA provides the voice of 1,900 companies committed to researching, developing andbringing new medicines to improve health and quality of life around the world. In Europe,
the pharmaceutical industry invests around 30 billion on research and development per
year and directly employs 700,000 people including 116,000 in R&D.
EFPIA members are committed to delivering innovative medicines to address unmet
needs of patients and reducing the burden of chronic diseases for Europe’s ageing
population. EFPIA believes in close cooperation with its stakeholders to help create
sustainable healthcare systems and to develop prompt responses to health threats inEurope.
For more information please visit:
http://www.efpia.eu(EFPIA)

http://efpia.jp/English/index-e.html (EFPIA Japan)

Contact：
Tetsu Owari, Chairman, PR committee
ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017
Boehringer Ingelheim Japan, Inc.
TEL: 03-6417-2223
Mail : tetsuya.owari@boehringer-ingelheim.com

2Dr. Carsten Brunn
Chairman of EFPIA Japan
Dr. Carsten Brunn has been President of Bayer Yakuhin Ltd. and Bayer HealthCare
Representative for Japan since March 1, 2013.
Dr. Brunn joined Bayer HealthCare in 2011 as Global Head of Primary Care within Bayer
HealthCare Pharmaceuticals based in Beijing, China.
Prior to joining Bayer HealthCare, he began his career at Eli Lilly and Company, holding
managerial positions in strategic planning in Germany, and in global marketing, sales
training and regional sales in the US. Later, Dr. Brunn worked for three companies insenior management positions, including Global Brand Leader at Novartis in Switzerland,and Vice-President, Asia Pacific, for Bausch and Lomb in Singapore.
Dr. Brunn graduated from the University of Freiburg, Germany, with an MSc. degree in
Pharmaceutical Science in 1996. In addition, he studied at the University of Washington,
USA, under a research scholarship. In 1999 he received his PhD in Chemistry from theUniversity of Hamburg. He completed his executive training at London Business School.
Born in Tübingen, Germany, in 1970, Dr. Carsten Brunn is married with one son.
Last revised September 2014###3